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Abstract: The incidence and severity of Clostridium difficile infection (CDI) have increased 
dramatically over the past decade. Its treatment, however, has largely remained the same with 
the exception of oral vancomycin use as a first-line agent in severe disease. From 1999 to 2004, 
20,642 deaths were attributed to CDI in the United States, almost 7 times the rate of all other 
intestinal infections combined. Worldwide, several major CDI outbreaks have occurred, and 
many of these were associated with the NAP1 strain. This ‘epidemic’ strain has contributed to 
the rising incidence and mortality of CDI. The purpose of this article is to review the current 
management, treatment, infection control, and prevention strategies that are needed to combat 
this increasingly morbid disease.
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Introduction to Clostridium difficile outbreaks
Clostridium difficile is a Gram-positive, anaerobic, spore-forming, toxin-producing 
bacillus that causes antibiotic-associated diarrhea and colitis. It is transmitted via the 
fecal–oral route among humans. It was first isolated in 1935 by Hall and O’Toole from 
the stool of healthy neonates.1 They chose the name ‘difficile’ because of the difficulty 
they had in culturing this anaerobic bacterium on conventional media. At that time, it 
was not known to cause disease in human beings although cytotoxin production was 
recognized. In the late 1970s, C. difficile toxins were identified as the main causative 
agents in antibiotic-associated pseudomembranous colitis.
Over the past 20 years, the incidence and severity of C. difficile infection (CDI) have 
increased substantially. This pathogen is now associated with a far higher incidence of 
hospitalizations than the more widely publicized methicillin-resistant Staphylococcus 
aureus.2 CDI can cause a spectrum of disease ranging from asymptomatic carriage 
to mild diarrhea to pseudomembranous colitis with sepsis, toxic megacolon, organ 
failure, and death. The rate of US hospital discharges with CDI listed as a diagnosis 
doubled from 31/100,000 population in 1996 to 61/100,000 in 2003. The rate was 
sevenfold higher in persons .65 years of age compared to the 45–64 years age group.2 
Mortality rates related to CDI also increased during the same time period, rising from 
5.7 deaths per million population in 1999 to 23.7 deaths per million population in 
2004, an increase of about 35% per year.3 From 1999 to 2004, CDI was reported as 
a cause of death in 20,642 persons in the United States, almost 7 times the rate of all 
other intestinal infections combined.3 In England, the UK Statistics Authority listed 
CDI as the primary cause of death in 499 people in 1999, a number that more than Risk Management and Healthcare Policy 2012:5 submit your manuscript | www.dovepress.com
Dovepress 
Dovepress
56
Martinez et al
tripled to 1998 in 2005 and then rose further to 3393 in 2006.4 
The causes of these dramatic increases in CDI incidence 
and mortality seem to be multifactorial resulting from an 
aging hospital population with complex comorbidities, 
ever increasing antibiotic use, and the emergence of more 
virulent strains including the BI/NAP1/027/toxinotype III 
strain – henceforth designated as NAP1.5–7
Several outbreaks of CDI occurred in 6 different states 
in the United States between 2000 and 2003.7 The major-
ity of isolates from the outbreaks belonged to the NAP1 
strain of C. difficile, which was first characterized in the 
1980s. A major difference in the newer NAP1 isolates 
when compared to earlier isolates was that the newer 
isolates exhibited high-level resistance to fluoroquinolones.7 
A similar NAP1 CDI outbreak also occurred in Quebec, 
Canada, in 2004. The incidence of CDI in Quebec had 
increased from 6 per 1000 admissions in 1997 to 22.5 per 
1000 admissions in 2004. The case-fatality rate of CDI also 
increased, rising from 1.5% of cases in 1997 to 6.9% in 
2004.5 An analysis of 157 stool isolates from this outbreak, 
which included most major hospitals in the Quebec area, 
showed that 83% (129 isolates) of the cases were due to the 
new NAP1 strain. The emergence of the new NAP1 strain 
coincides with the rising incidence and mortality of CDI 
and highlights the need for better prevention and treatment 
strategies for this reemerging pathogen.
Natural history and clinical 
presentation
The life cycle of C. difficile begins in the spore form. These 
spores are easily transmitted as they are resistant to heat, 
acid, and antibiotics. The spores can remain viable for 
months outside of the human body. In the hospital, they can 
be found on bedding, furniture, medical equipment, as well 
as on the skin and jewelry of caregivers.8 Once ingested, 
the spores pass through the upper digestive tract into the 
intestines where they can germinate and colonize the colon. 
A study showed that 21% of patients receiving antibiotics and 
admitted to a general medical ward were colonized by this 
bacterium.9 Healthy individuals are usually protected from 
CDI by the normal bacterial flora of the gut, which resists 
C. difficile’s colonization and growth. Disruption of the nor-
mal microflora by antibiotics allows C. difficile to proliferate, 
produce toxins, and cause disease.10 C. difficile induces diar-
rhea and colitis through the release of two protein exotoxins, 
toxin A and toxin B. Greater than 60% of the population has 
serum and colonic antibody responses to these toxins.11,12 
Low or absent concentrations of serum IgG antibody against 
C. difficile toxins has been shown to confer a greater risk of 
CDI among hospitalized patients who become colonized by 
this bacterium.13 Toxigenic C. difficile can be identified in 
more than 95% of pseudomembranous colitis cases and in 
15%–25% of antibiotic-associated diarrhea cases.14,15
The NAP1 strain was first identified in the 1980s by 
restriction endonuclease analysis (then named BI).5,7 
The recent North American and Quebec outbreaks used 
North American Field Pulse Type Analysis and PCR 
  ribotyping, and it is now referred to as NAP1, ribotype 027, or 
BI/NAP1/027. This strain is characterized by three potential 
virulence determinants. The first is a possible   enhancement 
of toxin A and toxin B production. The two toxin genes 
are found on the pathogenicity locus – a 5-gene region 
that includes the genes for toxin A (tcdA) and toxin B (tcdB) 
as well as three ancillary or regulatory genes (tcdC, tcdE, 
and tcdR) (Figure 1). The genes for toxins A and B are 
regulated by tcdR (  positive regulator) and tcdC (  negative 
regulator). The   outbreak strains from Quebec and the 
United States carry   deletion mutations in the tcdC   inhibitory 
gene. The resulting loss of this inhibitory gene product has 
been   postulated to increase toxin   production. However, 
more recent data challenge this   conclusion.16 The second 
  important factor in the NAP1   outbreak strain is high-level 
fluoroquinolone   resistance (marked resistance to gati-
floxacin, moxifloxacin, and levofloxacin). Such   resistance 
was not seen in the earlier   isolates from the 1980s and 
the 1990s.5,7 These   fluoroquinolone antibiotics are used 
commonly in the   hospital setting as   first-line treatment for 
  community-acquired pneumonia, urinary tract infection, and 
gastrointestinal   infection. It is thought that the widespread use 
of these   antibiotics is partly to blame for recent NAP1 CDI 
outbreaks. Analysis of risk factors in the Quebec outbreak 
showed that the odds ratio (OR) for fluoroquinolone use in 
patients with CDI when compared to control subjects was 3.9. 
Restricting and reducing the use of fluoroquinolones may be 
helpful in preventing and managing NAP1 outbreaks. A third 
potential virulence factor in this new strain is the presence 
of binary toxin. Binary toxin is encoded by cdtA and cdtB 
in a   separate region called the CDT locus. It is thought that 
binary toxin might have an additive enterotoxic effect with 
toxins A and B, but its role, if any, in the pathophysiology of 
CDI remains unclear.
C. difficile diarrhea and colitis usually present in 
patients who are undergoing antibiotic therapy (Figure 2). 
The most notorious antibiotics leading to this illness are 
clindamycin, ampicillin, amoxicillin, cephalosporins, and 
  fluoroquinolones. It has been reported that up to 96% of Risk Management and Healthcare Policy 2012:5 submit your manuscript | www.dovepress.com
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patients with symptomatic CDI received antibiotics within 
2 weeks of the onset of diarrhea.17 Other predisposing 
factors leading to disease include advanced age, nursing 
home residence, and hospitalization.5,18 Recent data show 
that the use of acid   suppressants are also associated with 
an increased risk of CDI.19,20 In the hospital, the most 
common presenting   symptom of CDI is diarrhea, with the 
passage of frequent loose or watery stools. Occult blood 
and mucus can be seen but hematochezia and/or melena 
are rare.21 Patients can present with more serious signs 
and symptoms including colonic ileus or toxic megacolon. 
The ileus   prevents diarrhea from occurring so these patients 
can present with minimal or no diarrhea leading to delays 
in diagnosis. The only clues to the diagnosis of CDI in 
these cases may be fever,   leukocytosis, and abdominal pain 
  associated with diffuse abdominal tenderness to palpation 
and/or abdominal   distention. Some patients may present 
with more fulminant disease, which can lead to shock, toxic 
megacolon, and/or multiorgan failure. The overall estimated 
case fatality rate of CDI is .2%.23
CDI can be diagnosed based on clinical suspicion (  usually 
diarrhea in a patient with current or recent antibiotic use) ide-
ally supported by the demonstration of toxinogenic C. difficile 
or C. difficile toxins in the stool.24 The most widely used 
diagnostic tests are enzyme immunoassays (EIAs) to detect 
C. difficile toxins A and B. These EIAs are rapid (2–4 hours), 
relatively inexpensive, and convenient but show limited sen-
sitivity with frequent falsely negative results.24,25 Accordingly, 
more sensitive tests including assays for clostridial glutamate 
dehydrogenase (used as an initial sensitive screening test 
with subsequent confirmation using a more specific assay), 
tissue culture cytotoxicity, and PCR are under evaluation as 
alternatives to toxin EIAs.
Management and therapeutic  
strategies: efficacy of metronidazole   
and vancomycin as first choice  
of treatment
The immediate goal of CDI therapy is to alleviate the active 
symptoms of diarrhea and colitis. The ultimate goal of 
treatment is the restoration of the normal bacterial flora of 
the gut and elimination of CDI. The ideal treatment for CDI 
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Figure 1 The pathogenicity locus of Clostridium difficile. The 19.6-kb pathogenicity locus encodes toxin A (tcdA), toxin B (tcdB), a positive regulator of toxin transcription 
(tcdR), and a putative negative regulator of transcription (tcdC). The function of the tcdE gene product is uncertain but may include the facilitation of toxin release by bacterial 
membrane lysis. The NAP-1/027 strain carries mutations in tcdC that prevent the expression of TcdC protein.
Copyright © 2008, Massachusetts Medical Society. Modified with permission from Kelly CP, Lamont JT. Clostridium difficile – more difficult than ever. N Engl J Med. 2008; 
359(18):1932–1940.36
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Figure 2 Pathogenesis of Clostridium difficile-associated diarrhea and colitis.
Copyright © 2001, elsevier. Reproduced with permission from Kyne L, Farrell R, 
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would not require the use of antibiotics. Patients diagnosed 
with acute CDI should have all unnecessary antibiotics 
stopped. In 1974, Tedesco et al reported that up to 10% of 
patients receiving clindamycin suffered from pseudomem-
branous colitis.10 When clindamycin was discontinued, all 
patients recovered from their illness. However, many patients 
who suffer from CDI require antibiotic therapy to combat 
the growth of C. difficile and possibly also to treat serious 
coexisting infections.
The mainstays of treatment for CDI for the past 30 years 
have been metronidazole or oral vancomycin.   Metronidazole 
is considered as first-line therapy for patients with mild to 
moderately severe CDI. Oral vancomycin has been reserved 
for patients who did not respond to or tolerate metronidazole, 
for patients with multiple recurrences of CDI, or for patients 
with severe disease. The published treatment failure rates 
of metronidazole and vancomycin before the year 2000 
were similar (2.5% and 3.5%, respectively). After 2000, the 
published treatment failure rates of metronidazole rose to 
18.2%, while that of vancomycin remained low at 2.8%.26–28 
This rise in treatment failure with metronidazole has 
  coincided with the recent dramatic increases in CDI incidence 
and severity. These issues resulted in an ongoing debate in 
the medical community as to whether vancomycin is superior 
to metronidazole and should, therefore, be used as first-line 
therapy for CDI despite concerns about higher drug cost 
and possibly increased nosocomial vancomycin resistance, 
particularly in enterococci.30,31
In 2007, Zar et al reported the results of a randomized, 
double-blind, placebo-controlled trial of oral vancomycin ver-
sus metronidazole for the treatment of CDI. The study showed 
an overall treatment response rate of 84% (66/79 patients) 
in the metronidazole group and 97% (69/71 patients) in the 
vancomycin group. What was most novel and   interesting in 
the study was that subjects were prospectively stratified based 
on CDI disease severity. In patients with mild disease, the 
overall response rate was slightly better in the vancomycin 
group (98%) than in the metronidazole group (90%), but the 
difference did not reach statistical significance (P = 0.36). 
Conversely, the response rate in subjects with severe disease 
was only 76% in the metronidazole group compared to 97% 
in the vancomycin group (P = 0.02).30 These data support the 
continued use of metronidazole in patients with mild CDI 
but indicate that oral vancomycin should be used as first-
line therapy for patients who present with severe infection. 
Unfortunately, there is no widely accepted method to define 
mild or severe CDI, and further studies are needed to validate 
predictive rules to identify the patients most likely to respond 
to oral vancomycin. However, the authors propose the scheme 
illustrated in Table 1.
Table 1 Classification and treatment of initial Clostridium difficile infection
Severity Clinical manifestations Treatment
Carrier No discernible clinical symptoms or signs No treatment is indicated
Mild to moderate Mild diarrhea , 12 stools/day 
Afebrile 
Mild to moderate abdominal discomfort or  
tenderness 
Nausea with rare or absent vomiting 
Leukocytosis , 20,000
Discontinuation of predisposing antibiotics 
Hydration 
Monitor clinical status 
isolation 
Oral metronidazole 500 mg 3 times daily or intravenous   
metronidazole 500 mg 3 times daily if not tolerating  
oral intake 
Oral vancomycin 125 mg 4 times daily if intolerant of 
metronidazole
Severe Severe diarrhea . 12 stools/day 
Pseudomembranous colitis 
Severe abdominal pain 
Nausea or vomiting 
ileus 
in intensive care unit 
Leukocytosis . 20,000 
Renal failure
As above plus 
    Oral vancomycin 125 mg 4 times daily in place of oral 
metronidazole
    Consider addition of intravenous metronidazole 
500 mg 3 times daily
    intravenous metronidazole 500 mg 3 times daily if not 
tolerating oral intake
Fulminant Toxic megacolon 
Peritonitis 
Renal failure 
Respiratory distress 
Hemodynamic instability
As above plus 
  Surgical consultation
    Oral vancomycin 125 mg 3 times daily and 
intravenous metronidazole 500 mg 3 times daily
  Consider iviG
Copyright © 2009, Elsevier. Modified with permission from Leffler DA, Lamont JT. Treatment of Clostridium difficile-associated disease. Gastroenterology. 2009;136(6):1899–1912.29
Abbreviations: BUN, blood urea nitrogen; iviG, intravenous immunoglobulin.Risk Management and Healthcare Policy 2012:5 submit your manuscript | www.dovepress.com
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The standard initial therapy for mild CDI is to 
  discontinue all antibiotics and monitor the patient’s progress. 
For mild CDI that persists, when other antibiotics cannot be 
  discontinued or when patients are frail, then metronidazole 
500 mg orally 3 times daily (or 250 mg orally 4 times daily) 
is often used for 10–14 days (Table 2). In patients who are 
unable to tolerate oral administration, parenteral or rectal 
administration can be used and leads to similar systemic 
and colonic drug levels. The initial starting dose for vanco-
mycin is 125 mg orally 4 times daily for 10–14 days. Oral 
  vancomycin is not degraded or absorbed by the gut and 
reaches the colon intact, which enables it to achieve high 
luminal   concentrations with minimal toxicity. On the other 
hand, intravenous   vancomycin is not secreted into the gut 
and is, therefore, not suitable for the treatment of CDI. In 
patients who   cannot tolerate oral administration of vanco-
mycin, intravenous metronidazole is the drug of choice. 
Vancomycin (500 mg 4 times daily) as   rectal enemas or via 
a nasogastric tube can be used to supplement intravenous 
metronidazole in patients with very severe CDI, who are 
unable to tolerate oral vancomycin.24,25,32
A difficult problem with CDI is recurrent   infection, 
which occurs in ∼15%–30% of patients who were 
  successfully treated with an initial course of metronidazole 
or vancomycin.33,34 The clinical features of recurrence are 
similar to the initial occurrence with the presence of diarrhea 
occurring usually within 2 weeks after discontinuation of 
therapy. However, recurrences can occur up to 3 months after 
stopping the initial antibiotic treatment. Patients with mild 
symptoms can be treated conservatively with   symptomatic 
management. Patients who require antibiotics are typically 
treated with a second course of the same antibiotic used 
to treat the initial attack, and this approach has a success 
rate of about 60%. Probiotics (such as   Lactobacillus spp. 
or   Saccharomyces   boulardii) may be used as an adjunctive 
therapy and may have some, limited efficacy in   preventing 
recurrence.33 Patients who are intolerant to metronida-
zole should be placed on oral vancomycin at a dose of 
125 mg 4 times daily and should be treated for a 14-day 
course.   Unfortunately, despite   successful treatment of a 
first   recurrence 45% of these patients will have a repeat 
occurrence. Multiple   recurrences are usually treated with 
a prolonged tapering course of oral vancomycin (Table 2). 
A suggested therapy for a second recurrence is the tapered 
and pulsed dosing of oral vancomycin over 51 days (Table 2). 
There are no   established guidelines for the treatment of 
further recurrences, but other agents, such as intravenous 
immunoglobulins, rifaximin, probiotics, or fecal transplan-
tion, have all been reported to be useful in uncontrolled 
studies.33,35–37 A newer promising treatment for prevention 
of recurrent CDI was recently published by Lowy et al.38 
This was a randomized, double-blind, placebo-controlled 
trial of two human monoclonal antibodies against C. dif-
ficile toxins A (CDA1) and B (CDB1). The antibodies were 
administered in conjunction with metronidazole or vanco-
mycin in patients receiving treatment for symptomatic CDI. 
The rate of recurrence was only 7% among patients treated 
with monoclonal antibodies versus 25% in the placebo group 
(P # 0.001). The recurrence rate for patients infected with 
the BI/NAP1/027 strain was 8% for the monoclonal antibody 
group versus 32% in the placebo group (P = 0.06). Once 
commercially available, this monoclonal antibody will likely 
be used in patients at high risk for recurrent CDI. Risk factors 
for recurrent CDI include low serum IgG antitoxin, a prior 
recurrence, older age, severe underlying medical   conditions, 
or a requirement for   concomitant antibiotic   treatment for 
additional infections.34,39
Table 2 Suggested approaches to therapy
initial episode
  Mild to moderate infection
      Metronidazole at a dose of 500 mg orally 3 times daily for 
10–14 days
      Severe infection or unresponsiveness to or intolerance to 
metronidazole
    vancomycin at a dose of 125 mg orally 4 times daily for 10–14 days
First recurrence
  Mild to moderate infection
      Metronidazole at a dose of 500 mg orally 3 times daily for 
10–14 days
      Severe infection or unresponsiveness to or intolerance to 
metronidazole
    vancomycin at a dose of 125 mg orally 4 times daily for 10–14 days
Second recurrence:a
  vancomycin in tapered and pulsed doses
    125 mg daily 4 times daily for 14 days
    125 mg daily 2 times daily for 7 days
    125 mg once daily for 7 days
    125 mg once every 2 days for 8 days (4 doses)
    125 mg once every 3 days for 15 days (5 doses)
Third recurrence
    vancomycin at a dose of 125 mg orally 4 times daily for 14 days, 
followed by rifaximin at a dose of 400 mg twice daily for 14 days
Other options for recurrent infection
    intravenous immunoglobulin at a dose of 400 mg/kg of body weight 
once every 3 weeks for a total of 2 or 3 doses
    Therapy with other microorganisms, including ‘fecal transplantation’
Notes: aA probiotic such as Saccharomyces boulardii or lactobacillus species may be 
added during the final 2 weeks of the vancomycin taper and for at least 4 weeks 
thereafter (preferably 8 weeks). However, the efficacy of probiotics in preventing 
recurrent C. difficile infection is unclear.
Copyright © 2008, Massachusetts Medical Society. Reproduced with permission 
from Kelly CP, Lamont JT. Clostridium difficile – more difficult than ever. N Engl J 
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Infection control and prevention 
strategies
The ultimate goal in combating disease is prevention and/or 
eradication. Previous studies have suggested the efficacy of 
specific infection-control measures in reducing the incidence 
of CDI. These include hand hygiene, contact precautions, 
environmental cleaning and disinfection, and restriction of 
antimicrobial use.24,25 Nonetheless, the recent epidemics of 
CDI bring to light the need for better preventive measures. 
C. difficile vaccines are in development but are not ready for 
use in the population.40 Therefore, the current focus remains 
on infection control.
In June 2000, a C. difficile outbreak occurred at a 
teaching hospital in Pittsburgh, PA.18 This outbreak resulted 
in 26 colectomies and 18 deaths. In response, a C. difficile 
prevention bundle was instituted and was followed by a 
78% decrease in the rate of CDI as well as a decrease in 
the number of severe CDI cases.41 The prevention bundle 
consisted of education, increased and early case finding, 
expanded infection-control measures, development of a 
CDI management team, and antimicrobial management. The 
education component consisted of a standardized education 
module with printable handouts for patients and providers. 
Nurses were given the authority to order testing for CDI, 
which allowed increased case finding. An e-mail alert system 
was also instituted, which encouraged attending physicians to 
test patients who were at high risk of having CDI. Expanded 
infection-control measures included environmental cleaning 
with bleach, electronic flags and alerts, hand hygiene with 
soap and water, prolonged duration of contact precautions 
beyond resolution of diarrhea, and infection-control audits. 
Finally, a formal antimicrobial management program was 
instituted, which required the prior approval of certain 
high-risk antibiotics by infectious diseases physicians and 
pharmacists.41
A similar bundle approach was recently instituted 
at a teaching hospital in Boston, MA. This study was an 
observational before–after study of adult patients admitted 
to a tertiary university-affiliated hospital during a 
4-year period from January 2004 to December 2008.42 
The   intervention included an educational campaign, a 
  prevention bundle, and a treatment bundle. The educational 
campaign taught all hospital personnel about the increasing 
incidence and severity of CDI and encouraged everyone 
to increase their level of suspicion for this diagnosis. The 
campaign encouraged hospital personnel to promptly 
  initiate diagnostic   testing, isolation precautions (including 
hand washing), and   treatment for those diagnosed with 
CDI. The prevention bundle gave   specific responsibilities 
to physicians, physician assistants, nurse practitioners, floor 
nurses, microbiology staff, infection-control   practitioners, 
and environmental services personnel (Table 3). The bundle 
also included specific infection-  control practices: 1) ‘Con-
tact Precautions Plus’ that included   emphasizing hand 
washing after every encounter with a patient with CDI and 
cleaning rooms with hypochlorite-based   disinfectant after a 
patient with CDI was discharged. 2) Laboratory   notification 
  procedures that included verbal   notification to floor nurses, 
e-mail alerts to hospital infections   preventionists when a 
patient had a positive toxin assay and steps to be taken in 
  coordinating infection control, and environmental services 
that aimed to decrease the   transmission of C.   difficile 
between patients. 3) A treatment bundle was created to 
standardize the treatment of patients with severe CDI 
and to provide guidelines for when to consider surgical 
consultation. The   incidence rate of health care-associated 
CDI decreased by 40% from 1.1 cases per 1000 patient 
days preintervention to 0.66 cases per 1000 patient days 
postintervention. This reduction was sustained over a 
21-month period.
Hand hygiene is an important component of most   hospital 
infection control and prevention programs.43–46 In many 
hospitals in the United States, the use of alcohol-based hand 
gels now far exceeds hand washing with soap and water as the 
primary hand hygiene method. One reason for the increased 
use of alcohol-based hand gels is that they are quick and 
effective.44 Proper hand hygiene is crucial in preventing the 
transmission of C. difficile in the hospital setting. In 1989, 
McFarland et al showed that 59% of hospital personnel   caring 
for patients with a positive C. difficile culture carried the 
organism on their hands.9 It is well known that alcohol-based 
hand gels do not kill the C. difficile spores. A recent study 
by Oughton et al evaluated different hand hygiene methods 
for efficacy in removing C. difficile. The study examined 
10 volunteers with hands experimentally contaminated by 
nontoxigenic C. difficile. The results showed that the   greatest 
reduction of C. difficile colony counts occurred by hand 
washing with soap and water, while the use of alcohol-based 
handrub was equivalent to no intervention.47 It is difficult to 
determine whether the increased usage of alcohol-based gels 
has played a role in the increasing incidence of C. difficile. 
Regardless, the current data provide preliminary support for 
the use of soap and water over hand gels for hospital personnel 
who are in contact with a C. difficile-infected patient.
Another  important  vector  for  the  transmission 
of C.   difficile is through the hospital environment.   Risk Management and Healthcare Policy 2012:5 submit your manuscript | www.dovepress.com
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C.   difficile can be found in the hospital on floors, bedrails, 
  windowsills,   commodes, toilets, call buttons, blood pressure 
cuffs,   electronic   thermometers, and bedsheets.48 Therefore, 
  disinfection of the contaminated hospital environment is 
essential to prevent the transmission of this nosocomial 
pathogen. Quaternary ammonium-based disinfectants are 
used commonly in the hospital setting but are not sporicidal 
against C. difficile.48,49 Disinfectants containing unbuffered 
hypochlorite (bleach), on the other hand, are sporicidal.49,50 
In 1988, Kaatz et al reported on the use of hypochlorite as 
a disinfectant during a C. difficile outbreak. The bacterium 
was recovered from 31% of environmental cultures obtained 
on the hospital wards. These wards were then disinfected 
with unbuffered hypochlorite, and the outbreak subsequently 
ended.51 A more recent study by Fawley et al compared the 
effects of five different cleaning agents against epidemic 
and nonepidemic C. difficile strains. This study showed 
that only chlorine-based germicides were able to   inactivate 
C. difficile spores.52 These studies support the use of 
  chlorine-based   disinfectants for preventing the   transmission 
of C. difficile.
Another potential prevention measure in the fight against 
C. difficile could be the restriction of   acid-  suppressive 
agents. Recent literature suggests that there is an   association 
Table 3 Clostridium difficile infection (CDi) checklist
Prevention checklist Treatment checklist
• When an MD, PA, NP, or RN suspects a patient has CDI:
Physician, Physician Assistant, or Nurse Practitioner:
□ initiate Contact Precautions Plus
□ Order stool C. difficile toxin testing
□ Discontinue non-essential antimicrobials
□ Discontinue all anti-peristaltic medications
Registered Nurse:
□ Obtain stool sample for C. difficile toxin test
□ Place patient in single-patient room
□ Place Contact Precautions Plus sign on patient’s door
□   ensure that gloves and gowns are easily accessible from  
patient’s room
□ Place dedicated stethoscope in patient’s room
□   Remind staff to wash hands with soap and water following  
patient contact
Microbiology Laboratory Staff Person:
□ Call relevant patient floor with positive C. difficile toxin test result
□ Provide daily list of positive test results for infection Control
Infection Control Practitioner:
□   Check microbiology results daily for positive C. difficile toxin results
□   Call relevant floor to confirm that patient with positive C. difficile  
toxin results is in a single-patient room and that the  
Contact Precautions Plus sign is on the patient’s door
□   Flag the patient’s C. difficile status in the hospital’s clinical  
information system or in the patient’s paper chart
□ Alert housekeeping that the patient is on Contact Precautions Plus
Environmental Services Staff Person:
□   Prior to discharge cleaning, check for Contact Precautions Plus sign  
on the patient’s door
□   if Contact Precautions Plus sign is on the door, clean the room  
with a bleach-based cleaning agent
□   Confirm for supervisor that bleach-based cleaning agent was  
used for discharge cleaning for every patient on  
Contact Precautions Plus
•   When an MD, PA, or NP diagnoses mild CDI:
All of the following criteria are present: diarrhea (,6 BM/day),  
no fever, wBC , 15,000, no peritoneal signs, and no evidence of sepsis
Physician, Physician Assistant, or Nurse Practitioner:
□ initiate oral metronidazole at dose 500 mg every 8 hours  
□   if no clinical improvement by 48–72 hours after diagnosis, treat patient  
as moderate CDi
□   Continue therapy for at least 14 days total and at least 10 days after 
symptoms have abated
•   When an MD, PA, or NP diagnoses moderate CDI:  
At least one of the following criteria is present: diarrhea (6–12 BM/day), 
fever 37.5–38.5°C, wBC 15,000–25,000, or frankly visible stable lower 
gastrointestinal bleeding
Physician, Physician Assistant, or Nurse Practitioner:
□ initiate oral vancomycin at dose 250 mg every 6 hours
□   if no clinical improvement by 48 hours, add iv metronidazole  
at dose 500 mg every 8 hours
□ Consider obtaining infectious disease consultation
□ Consider obtaining abdominal CT scan
□   Continue therapy for at least 14 days total and at least 10 days after 
symptoms have abated
•   When an MD, PA, or NP diagnoses severe CDI:
At least one of the following criteria is present: diarrhea (.12 BM/day), 
fever .38.5°C, wBC . 25,000, hemodynamic instability, marked and 
continuous abdominal pain, ileus, absence of bowel sounds, evidence  
of sepsis, or intensive care unit level of care required
Physician, Physician Assistant, or Nurse Practitioner:
□ Obtain immediate infectious disease consultation
□ Obtain immediate general surgery consultation
□ Obtain abdominal CT scan
□   initiate oral vancomycin at dose 250 mg every 6 hours together with 
iv metronidazole at dose 500 mg every 6 hours
□   Following consultation with general surgery regarding its use, consider 
rectal vancomycin
□ Ask general surgery service to assess the need for colectomy
Hospital interventions to decrease the incidence and mortality of healthcare-associated C. difficile infections. 
Notes: After the institution of this checklist along with other interventions, there was a 40% reduction in the incidence of CDi at this Boston hospital.
Copyright © 2009, University of Chicago Press. Reproduced with permission from Abbett SK, Yokoe DS, Lipsitz SR, et al. Proposed checklist of hospital interventions   
to decrease the incidence of healthcare-associated Clostridium difficile infection. Infect Control Hosp Epidemiol. 2009;30(11):1062–1069.42
Abbreviations:  MD, medical  doctor;  PA, physician  assistant;  NP, nurse  practitioner;  RN, registered  nurse;  BM, bowel  movement;  wBC, white  blood  cell  count;   
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between the use of proton pump inhibitors (PPIs) and CDI,19,20 
and multiple large studies now   support this finding.53–55 
Cunningham et al showed that PPI use within the preceding 
8 weeks prior to exposure was associated with an increased 
risk of C. difficile diarrhea, OR of 2.5, and 95% confidence 
interval (CI) of 1.5–4.2.20 In 2008, Aseeri et al reported 
similar results in a case control study, where CDI was 
associated with the use of PPI with an OR of 3.6 and 95% 
CI of 1.7–8.3.56 The   pathophysiology behind this association 
is not well understood, as C. difficile spores are known to be 
acid-resistant. C. difficile should be able to pass through the 
stomach despite its acidic   environment, so it is unclear as to 
how acid suppression might increase the risk of developing 
infection. Hypotheses include C.   difficile–  permissive changes 
in intestinal flora with increasing pH57 or potentially that 
the use of acid   suppressants is a marker for comorbidity, a 
well-established risk factor for CDI.58,59
The role of probiotics in the prevention of C.   difficile 
remains unclear.60,61 There are many studies in the   literature 
regarding probiotics in the prevention of   antibiotic-  associated 
diarrhea, but fewer studies looking at probiotics in the 
prevention of CDI. In 2004, Plummer et al reported a 
double-blind, placebo-controlled trial examining the role 
of   probiotics (Lactobacillus and Bifidobacterium) in the 
prevention of CDI.62 In this study, 150 consecutive patients 
receiving antibiotic therapy were randomized to receiving 
the probiotic or placebo. The results showed that, on the 
basis of developing diarrhea, only 2.9% of stool samples in 
the   probiotic group were positive for C. difficile-associated 
toxins versus 7.25% in the placebo-controlled group. Despite 
this finding, the total number of patients who tested positive 
for C. difficile was actually higher in the probiotic group 
(n = 11) than in the placebo group (n = 9), so the effect of 
the probiotic in this study is uncertain. S. boulardii does 
not appear to be   effective in primary prevention of CDI.33,63 
At this time, there is   insufficient evidence to support the 
widespread use of   probiotics for the primary prevention 
of CDI. Larger   randomized control trials are needed to 
    support its use.
Conclusion
The incidence and severity of CDI has increased over the 
past decade, and this infection is associated with an increased 
mortality due to an aging population, increased antibiotic use, 
and increased bacterial virulence. Despite this increasing 
severity, the mainstay of treatment has changed very little. 
Metronidazole is appropriate for mild to moderately severe 
CDI, while vancomycin is now recommended as first-line 
therapy for severe infection. Immune-based therapies, such 
as vaccines and passive immunotherapies, show promise but 
further studies need to be done. At this time, the focus of 
the medical community should be on   prevention strategies. 
Infection-control programs are essential and should be 
multifaceted to control the increasing incidence of this 
morbid disease.
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